Common use of Collaborator Funding Clause in Contracts

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD under this CRADA. If Collaborator has agreed to provide funds to ICD then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 20 contracts

Samples: Public Health Service, Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)

AutoNDA by SimpleDocs

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 12 contracts

Samples: Public Health Service (BriaCell Therapeutics Corp.), Development Agreement (Virpax Pharmaceuticals, Inc.), Cooperative Research and Development Agreement (Scopus BioPharma Inc.)

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD CDC under this CRADA. If Collaborator has agreed to provide funds to ICD CDC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD CDC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD CDC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 4 contracts

Samples: Public Health Service, Public Health Service, Public Health Service

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD under this CRADA. If Collaborator has agreed to provide funds to ICD then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds Rinds are received. ICD will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 2 contracts

Samples: Agreement (Tracon Pharmaceuticals, Inc.), Agreement (Tracon Pharmaceuticals Inc)

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein Research Plan or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report fiscal report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report final research report described in Paragraph 4.2.

Appears in 2 contracts

Samples: Cooperative Research and Development Agreement, Cooperative Research and Development Agreement

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be he used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 1 contract

Samples: Cooperative Research and Development Agreement (Edge Therapeutics, Inc.)

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report fiscal report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report final research report described in Paragraph 4.2.

Appears in 1 contract

Samples: Research and Development Agreement (Lumena Pharmaceuticals, Inc.)

AutoNDA by SimpleDocs

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD NCI under this CRADA. If Collaborator has agreed to provide funds to ICD NCI then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD NCI will not be obligated to perform any of the research and development activities specified herein Research Plan or to take any other action required by this CRADA until the funds are received. ICD NCI will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report fiscal report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report final research report described in Paragraph 4.2.

Appears in 1 contract

Samples: Health Service

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD FDA under this CRADA. If Collaborator has agreed to provide funds to ICD FDA then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD FDA will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD FDA will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 1 contract

Samples: Public Health Service (BG Medicine, Inc.)

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party IC will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide to the other Party Collaborator a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 1 contract

Samples: And Development Agreement (Exelixis, Inc.)

Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund ICD IC under this CRADA. If Collaborator has agreed to provide funds to ICD IC, then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, ICD IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. ICD IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2.

Appears in 1 contract

Samples: Cooperative Research and Development Agreement (Curative Biotechnology Inc)

Time is Money Join Law Insider Premium to draft better contracts faster.